NKG2D


Project-related publications

P1, P3, P6, P7, Z

The IL-7R antagonist Lusvertikimab reduces leukemic burden in xenograft-ALL via antibody-dependent cellular phagocytosis

Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J, Narbeburu E, Neyton SL, Déramé M, Pengam S, Vogiatzi F, Bornhauser B, Bourquin JP, Raffel S, Dovhan V, Schüler T, Escherich G, den Boer ML, Boer JM, Wessels W, Peipp M, Alten J, Antić Ž, Bergmann AK, Schrappe M, Cario G, Brüggemann M, Poirier N, Schewe DM.


Researchers

Prof. Dr. rer. nat. Matthias Peipp

Principle Investigator
Division of Antibody-based Immunotherapy / University Medical Center Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel
P7

Dr. rer. nat. Katja Klausz

Senior scientist
Division of Antibody-based Immunotherapy / University Medical Center Schleswig-Holstein, Campus Kiel, Clinic for Internal Medicine II, Hematology and Oncology / University Medical Center Schleswig-Holstein, Campus Kiel
P7

Participating Institutes